Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (654)	3/19/2003 6:56:24 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Oncology doesn't seem to be Biogen's idea about having a good time, so they have farmed out their cripto-project (as well as two others) to IDEC. SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2003--IDEC Pharmaceuticals Corporation (Nasdaq: IDPH - News) and Biogen, Inc. (Nasdaq:BGEN - News) today announced plans to co-develop three oncology therapeutics from Biogen's pipeline of early-stage development candidates. The collaboration leverages the companies' world-class capabilities in their respective areas of discovery research, development, and manufacturing. By working together, the companies expect these promising new therapeutics for patients with cancer to move forward more rapidly. The three oncology product candidates are: * An anti-lymphotoxin beta receptor (LTBR) monoclonal antibody. LTBR is a member of the TNF superfamily of cytokines. The activation of LTBR has been demonstrated to inhibit tumor growth in animal models. An agonist antibody against this target has been generated. * An anti-CRIPTO monoclonal antibody. Cripto is a novel cell surface signaling molecule that is over expressed in a multitude of solid tumors including breast, colon and lung. * An interferon beta (INF-b) gene delivery product for glioma that is in Phase I. INF-b gene delivery has exhibited direct and indirect anti-tumor activity and has the potential to treat a broad range of tumors with high unmet medical need.